content: <PAGE>
  
                         SECURITIES AND EXCHANGE COMMISSION
  
  
                               WASHINGTON, D.C. 20549
  
                                     -----------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
  
  
          Date of Report (Date of earliest event reported): March 18, 2002
  
  
  
  
                                   CONCEPTUS, INC.
                 (Exact name of registrant as specified in charter)
  
  <TABLE>
  <CAPTION>
                <S>                                    <C>                                     <C>
                 Delaware                               000-27596                               97-3170244
      (State or other jurisdiction of             (Commission file number)                   (I.R.S. employer
       incorporation or organization)                                                      identification no.)
  
  </TABLE>
  
  
                                 1021 Howard Avenue
                                San Carlos, CA 94070
                 (Address of principal executive offices) (Zip code)
  
  
  
         Registrant's telephone number, including area code: (650) 802-7240
  
  
                       -------------------------------------
  
  <PAGE>
  
  ITEM 5.  OTHER EVENTS.
  
           On March 18, 2002, Conceptus, Inc. issued a press release announcing
  plans to accelerate the submission of its Premarket Approval (PMA) application
  to the U.S. Food and Drug Administration (FDA). The Company now plans to submit
  the final PMA application for Essure in April of 2002, rather than by the end of
  June as previously announced. Text of the press release follows:
  
  
  SAN CARLOS, Calif. (March 18, 2002) - Conceptus, Inc. (NASDAQ NM: CPTS),
  developer of the non-incisional permanent birth control procedure Essure(TM),
  today announced plans to accelerate the submission of its Premarket Approval
  (PMA) application to the U.S. Food and Drug Administration (FDA). The Company
  now plans to submit the final PMA application for Essure in April of 2002,
  rather than by the end of June as previously announced.
  
  Due to the strength of the clinical data to date, the Company submitted a
  written proposal to FDA requesting that the PMA application be filed with
  one-year data on 350 women in the Pivotal trial, instead of the previously
  agreed to 400 women, if an effectiveness rate of greater than 99% could be
  established. The FDA has accepted the proposal and the Company plans to file the
  PMA application in April. As part of the proposal, the Company agreed to update
  the PMA application in June with one-year data on 400 women, so that the FDA's
  OB/GYN Advisory Panel could convene after having reviewed the data on 400 women.
  
  Based on the new time line for the PMA submission and recent FDA
  correspondence, Conceptus believes that the PMA application, if deemed
  "fileable," will be brought before the Advisory Panel in July or October of
  2002.
  
  "We have worked closely with the FDA during all phases of our clinical trials
  and, more recently, during our PMA preparations as well. We have been very
  appreciative of the Agency's input throughout the course of the Essure product
  development, and of their willingness to consider the least burdensome and most
  expeditious route to PMA filing," said Cindy Domecus, Senior Vice President for
  Clinical Research and Regulatory Affairs at Conceptus.
  
  "While additional steps remain to submit our PMA and secure U.S. regulatory
  clearance for Essure, we are encouraged that Essure could be available in our
  most important market ahead of plan," commented Steven Bacich, Chief Executive
  Officer. "We are delighted that clinical results in the pivotal study to date,
  combined with the results from our Phase II study are so strong. It is the
  strength of the data from both studies to date, and the expertise of Cindy
  Domecus and the entire regulatory and clinical research staffs in working
  together with the FDA, that enable us to pursue an accelerated regulatory time
  line."
  
  To date, Conceptus has submitted two modules of the Essure PMA application, and
  the FDA has accepted and closed the first module.
  
  
  
                                          2
  
  <PAGE>
  
  PERMANENT BIRTH CONTROL
  
  Surgical tubal ligation has become the most common form of birth control
  worldwide, despite the fact that it is invasive and costly. About 93% of the
  procedures in the U.S. are performed in a hospital or surgi-center under general
  anesthesia, requiring between four to five hours of hospital recovery time and
  an average of three to 10 days before returning to regular activities. An Essure
  procedure does not require cutting or penetrating the abdomen, and can be
  performed in a less costly procedure setting without general anesthesia.
  Accordingly, a woman is expected to average about 30 minutes for an Essure
  procedure and to return home about 45 minutes after the procedure is completed.
  92% of Essure patients who were employed returned to work in one day or less,
  excluding the day of the procedure. Reliance on Essure does not involve taking
  drugs or hormones.
  
  ABOUT CONCEPTUS
  
  Conceptus, Inc. is developing Essure, an investigational medical device and
  procedure in the U.S., which is designed to provide a non-incisional alternative
  to tubal ligation, the leading form of contraception worldwide. Data from the
  United Nations show that worldwide, 33% of reproductive couples using
  contraception rely on surgical tubal ligation. Additionally, a survey performed
  by the United States Centers for Disease Control and Prevention indicates that
  surgical tubal ligation continues to be the most prevalent form of contraception
  in the United States, and that 35% of women age 35-44 have had a surgical tubal
  sterilization. An estimated 700,000 to 800,000 surgical tubal ligations are
  performed each year in the United States.
  
  The Essure procedure is based on a unique and proprietary catheter delivery
  system for minimally invasive transcervical tubal access. Additional information
  about Conceptus and the Essure procedure is available at www.conceptus.com.
                                                           -----------------
  
           Except for the historical information contained herein, the matters
  discussed in this press release are forward-looking statements, the accuracy of
  which is necessarily subject to risks and uncertainties. The receipt of
  regulatory approvals, results of product development programs, and clinical
  efficacy of and market demand for our product, among other matters discussed in
  this release, may differ significantly from the discussion of such matters in
  the forward-looking statements. Such differences may be based upon factors such
  as strategic planning decisions by management, re-allocation of internal
  resources, performance of independent distributors, delays by regulatory
  authorities, scientific advances by third parties, introduction of competitive
  products, as well as those factors set forth in the Company's Annual Report on
  Form 10-K for the year ended December 31, 2000 and other filings with the
  Securities and Exchange Commission.
  
  
                                        # # #
  
  
  
                                          3
  
  <PAGE>
  
                                     SIGNATURES
  
       Pursuant to the requirements of the Securities Exchange Act of 1934, the
  registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                 CONCEPTUS, INC.
                                 (Registrant)
  
  
                                 By:  /s/ Glen K. Furuta
                                    ----------------------------------------------
                                          Glen K. Furuta
                                          Vice President, Finance & Administration
                                          and Chief Financial Officer
  
  
  Dated:   March 21, 2002
  
  
  
                                          4
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.txt", "description": "FORM 8-K", "secsgml_size_bytes": 8043}]
metadata_filer: {"company-data": {"conformed-name": "CONCEPTUS INC", "cik": "0000896778", "assigned-sic": "3841", "irs-number": "973170244", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-27596", "film-number": "02582238"}, "business-address": {"street1": "1021 HOWARD AVE", "city": "SAN CARLOS", "state": "CA", "zip": "94070", "phone": "4158027240"}, "mail-address": {"street1": "1021 HOWARD AVENUE", "city": "SAN CARLOS", "state": "CA", "zip": "94070"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                                     -----------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(D) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of Report (Date of earliest event reported): March 18, 2002
  
                                   CONCEPTUS, INC.
                 (Exact name of registrant as specified in charter)
  Delaware                               000-27596                               97-3170244
      (State or other jurisdiction of             (Commission file number)                   (I.R.S. employer
       incorporation or organization)                                                      identification no.)
  1021 Howard Avenue
                                San Carlos, CA 94070
                 (Address of principal executive offices) (Zip code)
  
         Registrant's telephone number, including area code: (650) 802-7240
  
                       -------------------------------------
  ITEM 5.  OTHER EVENTS.
  
           On March 18, 2002, Conceptus, Inc. issued a press release announcing
  plans to accelerate the submission of its Premarket Approval (PMA) application
  to the U.S. Food and Drug Administration (FDA). The Company now plans to submit
  the final PMA application for Essure in April of 2002, rather than by the end of
  June as previously announced. Text of the press release follows:
  
  SAN CARLOS, Calif. (March 18, 2002) - Conceptus, Inc. (NASDAQ NM: CPTS),
  developer of the non-incisional permanent birth control procedure Essure(TM),
  today announced plans to accelerate the submission of its Premarket Approval
  (PMA) application to the U.S. Food and Drug Administration (FDA). The Company
  now plans to submit the final PMA application for Essure in April of 2002,
  rather than by the end of June as previously announced.
  
  Due to the strength of the clinical data to date, the Company submitted a
  written proposal to FDA requesting that the PMA application be filed with
  one-year data on 350 women in the Pivotal trial, instead of the previously
  agreed to 400 women, if an effectiveness rate of greater than 99% could be
  established. The FDA has accepted the proposal and the Company plans to file the
  PMA application in April. As part of the proposal, the Company agreed to update
  the PMA application in June with one-year data on 400 women, so that the FDA's
  OB/GYN Advisory Panel could convene after having reviewed the data on 400 women.
  
  Based on the new time line for the PMA submission and recent FDA
  correspondence, Conceptus believes that the PMA application, if deemed
  "fileable," will be brought before the Advisory Panel in July or October of
  2002.
  
  "We have worked closely with the FDA during all phases of our clinical trials
  and, more recently, during our PMA preparations as well. We have been very
  appreciative of the Agency's input throughout the course of the Essure product
  development, and of their willingness to consider the least burdensome and most
  expeditious route to PMA filing," said Cindy Domecus, Senior Vice President for
  Clinical Research and Regulatory Affairs at Conceptus.
  
  "While additional steps remain to submit our PMA and secure U.S. regulatory
  clearance for Essure, we are encouraged that Essure could be available in our
  most important market ahead of plan," commented Steven Bacich, Chief Executive
  Officer. "We are delighted that clinical results in the pivotal study to date,
  combined with the results from our Phase II study are so strong. It is the
  strength of the data from both studies to date, and the expertise of Cindy
  Domecus and the entire regulatory and clinical research staffs in working
  together with the FDA, that enable us to pursue an accelerated regulatory time
  line."
  
  To date, Conceptus has submitted two modules of the Essure PMA application, and
  the FDA has accepted and closed the first module.
  
                                          2
  PERMANENT BIRTH CONTROL
  
  Surgical tubal ligation has become the most common form of birth control
  worldwide, despite the fact that it is invasive and costly. About 93% of the
  procedures in the U.S. are performed in a hospital or surgi-center under general
  anesthesia, requiring between four to five hours of hospital recovery time and
  an average of three to 10 days before returning to regular activities. An Essure
  procedure does not require cutting or penetrating the abdomen, and can be
  performed in a less costly procedure setting without general anesthesia.
  Accordingly, a woman is expected to average about 30 minutes for an Essure
  procedure and to return home about 45 minutes after the procedure is completed.
  92% of Essure patients who were employed returned to work in one day or less,
  excluding the day of the procedure. Reliance on Essure does not involve taking
  drugs or hormones.
  
  ABOUT CONCEPTUS
  
  Conceptus, Inc. is developing Essure, an investigational medical device and
  procedure in the U.S., which is designed to provide a non-incisional alternative
  to tubal ligation, the leading form of contraception worldwide. Data from the
  United Nations show that worldwide, 33% of reproductive couples using
  contraception rely on surgical tubal ligation. Additionally, a survey performed
  by the United States Centers for Disease Control and Prevention indicates that
  surgical tubal ligation continues to be the most prevalent form of contraception
  in the United States, and that 35% of women age 35-44 have had a surgical tubal
  sterilization. An estimated 700,000 to 800,000 surgical tubal ligations are
  performed each year in the United States.
  
  The Essure procedure is based on a unique and proprietary catheter delivery
  system for minimally invasive transcervical tubal access. Additional information
  about Conceptus and the Essure procedure is available at www.conceptus.com.
                                                           -----------------
  
           Except for the historical information contained herein, the matters
  discussed in this press release are forward-looking statements, the accuracy of
  which is necessarily subject to risks and uncertainties. The receipt of
  regulatory approvals, results of product development programs, and clinical
  efficacy of and market demand for our product, among other matters discussed in
  this release, may differ significantly from the discussion of such matters in
  the forward-looking statements. Such differences may be based upon factors such
  as strategic planning decisions by management, re-allocation of internal
  resources, performance of independent distributors, delays by regulatory
  authorities, scientific advances by third parties, introduction of competitive
  products, as well as those factors set forth in the Company's Annual Report on
  Form 10-K for the year ended December 31, 2000 and other filings with the
  Securities and Exchange Commission.
  
                                        # # #
  
                                          3
  SIGNATURES
  
       Pursuant to the requirements of the Securities Exchange Act of 1934, the
  registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                 CONCEPTUS, INC.
                                 (Registrant)
  
                                 By:  /s/ Glen K. Furuta
                                    ----------------------------------------------
                                          Glen K. Furuta
                                          Vice President, Finance & Administration
                                          and Chief Financial Officer
  
  Dated:   March 21, 2002
  
                                          4